Combining Immunotherapy and Targeted Therapy for Pancreatic Cancer
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
LMB-100 is a lab-created protein that targets mesothelin. It is being tested against pancreatic cancer and other solid tumors in a clinical trial.
A clinical trial tests the safety and effectiveness of tumor-associated antigen-specific cytotoxic T lymphocytes, which target specific tumor proteins.
In a clinical trial, the new drug sapanisertib is being tested for its effectiveness against pancreatic neuroendocrine tumors (PNETs).
Pancreatic neuroendocrine tumors (P-NETs) make up less than 5 percent of all pancreatic cancers. Unlike pancreatic ductal adenocarcinomas (PDAs), P-NETs…
A clinical trial for some cancers including pancreatic cancer tests the effectiveness of a checkpoint inhibitor and an antisense oligonucleotide inhibitor.
Researchers are trying kinase inhibitors that are effective for breast cancer, colorectal cancer, and melanoma on pancreatic cancer.
In a clinical trial, a new class of breast cancer drug called a kinase inhibitor is being tested to treat pancreatic cancer.
Researchers are adding the drug decitabine to gemcitabine, in a clinical trial for patients with advanced cancer that is not responding to treatment.
A phase I clinical trial is testing the effectiveness of a platinum-based drug for BRCA carriers with pancreatic, breast, and other cancers.